Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | TDO2 | P48775 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793750 | 0.84 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL3497181 | 0.84 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL4731645 | 0.83 | METAP2 (0.40) | NOS1AXLMETAP2CYP1A2PTK2 | |
| SCHEMBL31148280 | 0.83 | NOS1 (0.52) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL14553409 | 0.83 | NOS1 (0.52) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL31358108 | 0.83 | METAP2 (0.40) | NOS1AXLMETAP2CYP1A2PTK2 | |
| SCHEMBL25469229 | 0.76 | MAPT (0.43) | METAP2IDO1PTK2BRAFEIF2AK3 | |
| SCHEMBL30918002 | 0.76 | NOS1 (0.46) | NOS1METAP2CYP1A2BRAFEIF2AK3 | |
| SCHEMBL16059776 | 0.76 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL23478332 | 0.76 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024189488-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | ASTRAZENECA AB (SE) | 2024-09-19 | — | — | WO | disclosed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-1513832-B1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| EP-1513832-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005004801-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC N-SUBSTITUTED PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| WO-2004043337-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-04-01 | — | — | US | disclosed |
| US-20040063746-A1 | Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004011425-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC UREIDO AND THIOUREIDO PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040006090-A1 | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| WO-2004000210-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC SULFONYLUREIDO PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, NLRP1, PYCARD | NOS1 568/4885AXL 4342/4885METAP2 2991/4885 |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | IDO2, IDO1, INMT | NOS1 1566/4885AXL 4412/4885METAP2 761/4885 |
| US-20040063744-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | NOS1 658/4885AXL 4753/4885METAP2 1921/4885 |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | NOS1 658/4885AXL 4753/4885METAP2 1921/4885 |
| US-20040006090-A1 | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives | IDO1, IDO2, INMT | NOS1 418/4885AXL 3903/4885METAP2 2984/4885 |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | NOS1 785/4885AXL 4160/4885METAP2 3116/4885 |
| US-20040063746-A1 | Indole, azaindole and related heterocyclic ureido and thioureido piperazine derivatives | IDO1, IDO2, TPMT | NOS1 389/4885AXL 3064/4885METAP2 1114/4885 |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, CASP1, PYCARD | NOS1 489/4885AXL 4367/4885METAP2 3107/4885 |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | NOS1 785/4885AXL 4160/4885METAP2 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.